Joshua Richter, MD

Joshua Richter, MD, elaborates on the best scenarios for certain CELMoD-based treatments for patients with multiple myeloma.

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Joshua Richter, MD, discusses the FDA approval of linvoseltamab for relapsed or refractory multiple myeloma.

Joshua Richter, MD, discusses the identification of early abnormalities that may indicate that a patient has multiple myeloma.

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

Joshua Richter, MD, discusses the role of bispecific antibody therapy in myeloma and expands on toxicity management for these agents.

Joshua Richter, MD, FACP, presents recent National Comprehensive Cancer Network (NCCN) guideline updates in the treatment of multiple myeloma.

Joshua Richter, MD, discusses findings from the phase 1/2 LINKER-MM1 trial (NCT03761108) in multiple myeloma.

Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.

Ola Landgren, MD, PhD, leads the discussion on the use of cilta-cel and ide-cel in newly diagnosed multiple myeloma and the sequencing of available therapies in transplant-eligible and transplant-ineligible patients.

Experts discuss emerging BCMA-targeting CAR T-cell therapies under investigation for treating multiple myeloma and barriers to CAR T access.

Katja Weisel, MD, reviews the study results from the KarMMa study evaluating the use of ide-cel in patients with relapsed/refractory multiple myeloma.

Ola Landgren, MD, PhD, leads a review of the updated efficacy and safety results and subgroup analysis of the CARTITUDE-1 study for patients with relapsed/refractory multiple myeloma.

Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.

Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Sagar Lonial, MD, reviews key takeaways from the DREAMM-2 trial, and Katja Weisel, MD, comments on the potential use of belantamab mafodotin in the early relapse setting for multiple myeloma.

Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.

Sagar Lonial, MD; Joshua Richter, MD; and Ola Landgren, MD, PhD, comment on the selection of the appropriate treatment regimen at first relapse, including CD38-based, non-CD38–based and non-PI–based treatment regimens for multiple myeloma, and discuss their approach to assessing treatment response.

Ola Landgren, MD, PhD, reviews the results and clinical implications of the IKEMA study for patients with relapsed/refractory multiple myeloma.

Katja Weisel, MD, leads a review of the study design and updated efficacy and safety results of the phase 3 CANDOR study for patients with relapsed/refractory multiple myeloma.

Ola Landgren, MD, PhD; Sagar Lonial, MD; and Joshua Richter, MD, review current available treatment options and factors to consider when selecting therapy for patients with multiple myeloma who experience a first relapse.

Katja Weisel, MD, and Joshua Richter, MD, define biochemical vs clinical relapses in multiple myeloma and share recommendations for initiating treatment at either stage.

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.